Herantis Pharma Announces Successful HER-096 Initial Results with Nanoform Technology
Herantis Pharma Plc Press release 24 Mar 2022 at 09:00 am EET Herantis Pharma Plc (“Herantis”), an innovative biotech company developing new disease modifying therapies for Parkinson’s disease, today announced: · Results of proof-of-concept study demonstrating successful nanoforming of HER-096 into nanoparticles · Further exploration the applicability of Nanoform’s technology in the development of an oral dosage form based on HER-096 nanoparticles. Herantis has previously shown that HER-096 penetrates the blood brain barrier (BBB) and enters the brain in therapeutic